|
|
 | | | |
- close
- close
- close
- close
VIA Pharmaceuticals (VIAP) |
QUOTE AND NEWS
Globe Newswire
May 8
Comment
OSAKA, Japan, May 8, 2012 (GLOBE NEWSWIRE) -- Santen Pharmaceutical Co., Ltd. (Head office: Osaka, hereafter referred to as "Santen") announced today that Santen and Bayer Yakuhin, Ltd. (Head office: Osaka, hereafter referred to as "Bayer Yakuhin")
MedPage Today
Mar 8
Comment
(MedPage Today) -- Bevacizumab (Avastin) may improve cardiac function and cut down on potentially life-threatening nose bleeds from a rare genetic vascular disorder known as hemorrhagic telangiectasia, preliminary results suggested.
MedPage Today
Sep 29
Comment
STOCKHOLM (MedPage Today) -- Patients who've undergone treatment for metastatic colorectal cancer had "statistically significant and clinically meaningful" improvement in survival when also given a multitargeted angiogenesis inhibitor,...
FierceBiotech
Jun 17
Comment
Regeneron Pharmaceuticals ($REGN) has passed a key test at an FDA advisory committee meeting on its experimental eye drug. The expert panel voted unanimously that the treatment, called VEGF Trap-Eye, should be approved to treat a neurovascular...
MarketWatch
Jun 17
Comment
Regeneron Pharmaceuticals Inc. shares were halted trading by Nasdaq on Friday as the U.S. Food and Drug Administration and the Dermatologic and Ophthalmic Drugs Advisory Committee meet to discuss the company's license application for treating...
FierceBiotech
Jun 15
Comment
Today FDA staffers published an even-handed evaluation of VEGF Trap Eye (aflibercept). As Bloomberg reports, the drug helps prevent vision loss just as well as a rival treatment on the market. And it has a more attractive dosing regimen to...
MarketWatch
Jun 15
Comment
Shares of Regeneron Pharmaceuticals were up 10% at $60.25 in early trading Wednesday, ahead of a U.S. Food and Drug Administration advisory panel meeting on Friday that will discuss whether the agency should approve the company's eye medication...
MedPage Today
May 5
Comment
(MedPage Today) -- FORT LAUDERDALE, Fla. -- An investigational drug for treating "wet" age-related macular degeneration (AMD) was as effective as ranibizumab (Lucentis) even when dosed every other month, two identical one-year studies showed.
StreetInsider.com
Apr 27
Comment
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/Regeneron+%28REGN%29+Reports+Positive+Results+for+VEGF+Trap-Eye+in+Second+Phase+3+Study+in+Central+Retinal+Vein+Occlusion/6453072.html for the full story.
Suggest other news sources for this topic
more ▼WIKI ANALYSIS
WIKI ANALYSIS
 |
The article on this company has not been written yet. If you're the first person to write this article, it's a sure thing that you'll be credited as a Top Contributor. For tips on getting started, check out the sample article. |
| |||||||
